Global Fragment-based Drug Discovery Market Overview:
Global Fragment-based Drug Discovery Market Is Expected to Grow at A Significant Growth Rate, And the Forecast Period Is 2025-2032, Considering the Base Year As 2024.
Global Fragment-based Drug Discovery Market Report 2025 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2025-2032.This research study of Fragment-based Drug Discovery involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Fragment-based Drug Discovery Market:
The Fragment-based Drug Discovery Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Fragment-based Drug Discovery Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Fragment-based Drug Discovery Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Fragment-based Drug Discovery market has been segmented into:
Fragment Screening
Fragment Optimization
By Application, Fragment-based Drug Discovery market has been segmented into:
Biopharmaceutical Companies
Academic & Research Institutions
Contract Research Organizations).
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Fragment-based Drug Discovery market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Fragment-based Drug Discovery market.
Top Key Players Covered in Fragment-based Drug Discovery market are:
Akaal Pharma Pty. Ltd.
Algorae Pharmaceuticals Ltd.
Aragen Life Sciences Ltd.
Beactica Therapeutics AB
Carna Biosciences Inc.
Charles River Laboratories International Inc.
Crelux
Evotec SE
Marsala Biotech Inc.
PsychoGenics Inc.
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Industry Dynamics and Opportunity Analysis
3.1.1 Growth Drivers
3.1.2 Limiting Factors
3.1.3 Growth Opportunities
3.1.4 Challenges and Risks
3.2 Market Trend Analysis
3.3 Strategic Pestle Overview
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Mapping
3.6 Regulatory Framework
3.7 Princing Trend Analysis
3.8 Patent Analysis
3.9 Technology Evolution
3.10 Investment Pockets
3.11 Import-Export Analysis
Chapter 4: Fragment-based Drug Discovery Market Type
4.1 Fragment-based Drug Discovery Market Snapshot and Growth Engine
4.2 Fragment-based Drug Discovery Market Overview
4.3 Fragment Screening
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Fragment Screening: Geographic Segmentation Analysis
4.4 Fragment Optimization
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Fragment Optimization: Geographic Segmentation Analysis
Chapter 5: Fragment-based Drug Discovery Market Application
5.1 Fragment-based Drug Discovery Market Snapshot and Growth Engine
5.2 Fragment-based Drug Discovery Market Overview
5.3 Biopharmaceutical Companies
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Biopharmaceutical Companies: Geographic Segmentation Analysis
5.4 Academic & Research Institutions
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Academic & Research Institutions: Geographic Segmentation Analysis
5.5 Contract Research Organizations).
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Contract Research Organizations).: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Fragment-based Drug Discovery Market Share by Manufacturer (2025)
6.1.3 Concentration Ratio(CR5)
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 AKAAL PHARMA PTY. LTD.; ALGORAE PHARMACEUTICALS LTD.; ARAGEN LIFE SCIENCES LTD.; BEACTICA THERAPEUTICS AB; CARNA BIOSCIENCES
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Operating Business Segments
6.2.5 Product Portfolio
6.2.6 Business Performance
6.2.7 Key Strategic Moves and Recent Developments
6.3 INC.; CHARLES RIVER LABORATORIES INTERNATIONAL
6.4 INC.; CRELUX; EVOTEC SE; MARSALA BIOTECH INC.; PSYCHOGENICS
6.5 INC.
Chapter 7: Global Fragment-based Drug Discovery Market By Region
7.1 Overview
7.2. North America Fragment-based Drug Discovery Market
7.2.1 Historic and Forecasted Market Size by Segments
7.2.2 Historic and Forecasted Market Size By Type
7.2.2.1 Fragment Screening
7.2.2.2 Fragment Optimization
7.2.3 Historic and Forecasted Market Size By Application
7.2.3.1 Biopharmaceutical Companies
7.2.3.2 Academic & Research Institutions
7.2.3.3 Contract Research Organizations).
7.2.4 Historic and Forecast Market Size by Country
7.2.4.1 US
7.2.4.2 Canada
7.2.4.3 Mexico
7.3. Eastern Europe Fragment-based Drug Discovery Market
7.3.1 Historic and Forecasted Market Size by Segments
7.3.2 Historic and Forecasted Market Size By Type
7.3.2.1 Fragment Screening
7.3.2.2 Fragment Optimization
7.3.3 Historic and Forecasted Market Size By Application
7.3.3.1 Biopharmaceutical Companies
7.3.3.2 Academic & Research Institutions
7.3.3.3 Contract Research Organizations).
7.3.4 Historic and Forecast Market Size by Country
7.3.4.1 Russia
7.3.4.2 Bulgaria
7.3.4.3 The Czech Republic
7.3.4.4 Hungary
7.3.4.5 Poland
7.3.4.6 Romania
7.3.4.7 Rest of Eastern Europe
7.4. Western Europe Fragment-based Drug Discovery Market
7.4.1 Historic and Forecasted Market Size by Segments
7.4.2 Historic and Forecasted Market Size By Type
7.4.2.1 Fragment Screening
7.4.2.2 Fragment Optimization
7.4.3 Historic and Forecasted Market Size By Application
7.4.3.1 Biopharmaceutical Companies
7.4.3.2 Academic & Research Institutions
7.4.3.3 Contract Research Organizations).
7.4.4 Historic and Forecast Market Size by Country
7.4.4.1 Germany
7.4.4.2 UK
7.4.4.3 France
7.4.4.4 The Netherlands
7.4.4.5 Italy
7.4.4.6 Spain
7.4.4.7 Rest of Western Europe
7.5. Asia Pacific Fragment-based Drug Discovery Market
7.5.1 Historic and Forecasted Market Size by Segments
7.5.2 Historic and Forecasted Market Size By Type
7.5.2.1 Fragment Screening
7.5.2.2 Fragment Optimization
7.5.3 Historic and Forecasted Market Size By Application
7.5.3.1 Biopharmaceutical Companies
7.5.3.2 Academic & Research Institutions
7.5.3.3 Contract Research Organizations).
7.5.4 Historic and Forecast Market Size by Country
7.5.4.1 China
7.5.4.2 India
7.5.4.3 Japan
7.5.4.4 South Korea
7.5.4.5 Malaysia
7.5.4.6 Thailand
7.5.4.7 Vietnam
7.5.4.8 The Philippines
7.5.4.9 Australia
7.5.4.10 New Zealand
7.5.4.11 Rest of APAC
7.6. Middle East & Africa Fragment-based Drug Discovery Market
7.6.1 Historic and Forecasted Market Size by Segments
7.6.2 Historic and Forecasted Market Size By Type
7.6.2.1 Fragment Screening
7.6.2.2 Fragment Optimization
7.6.3 Historic and Forecasted Market Size By Application
7.6.3.1 Biopharmaceutical Companies
7.6.3.2 Academic & Research Institutions
7.6.3.3 Contract Research Organizations).
7.6.4 Historic and Forecast Market Size by Country
7.6.4.1 Turkiye
7.6.4.2 Bahrain
7.6.4.3 Kuwait
7.6.4.4 Saudi Arabia
7.6.4.5 Qatar
7.6.4.6 UAE
7.6.4.7 Israel
7.6.4.8 South Africa
7.7. South America Fragment-based Drug Discovery Market
7.7.1 Historic and Forecasted Market Size by Segments
7.7.2 Historic and Forecasted Market Size By Type
7.7.2.1 Fragment Screening
7.7.2.2 Fragment Optimization
7.7.3 Historic and Forecasted Market Size By Application
7.7.3.1 Biopharmaceutical Companies
7.7.3.2 Academic & Research Institutions
7.7.3.3 Contract Research Organizations).
7.7.4 Historic and Forecast Market Size by Country
7.7.4.1 Brazil
7.7.4.2 Argentina
7.7.4.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Fragment-based Drug Discovery Scope:
|
Report Data
|
Fragment-based Drug Discovery Market
|
|
Fragment-based Drug Discovery Market Size in 2025
|
USD XX million
|
|
Fragment-based Drug Discovery CAGR 2025 - 2032
|
XX%
|
|
Fragment-based Drug Discovery Base Year
|
2024
|
|
Fragment-based Drug Discovery Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Akaal Pharma Pty. Ltd., Algorae Pharmaceuticals Ltd., Aragen Life Sciences Ltd., Beactica Therapeutics AB, Carna Biosciences Inc., Charles River Laboratories International Inc., Crelux, Evotec SE, Marsala Biotech Inc., PsychoGenics Inc..
|
|
Key Segments
|
By Type
Fragment Screening
Fragment Optimization
By Applications
Biopharmaceutical Companies
Academic & Research Institutions
Contract Research Organizations).
|
